Plant Production of Vaccine Against HPV: A New Perspectives

Šmídková, Markéta; Holá, Marcela; Brouzdová, Jitka; Angelis, Karel J.

doi:10.5772/28948

Cited by 1 publication

(1 citation statement)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Постоянный синтез и высокий уровень содержания в тканях делает их почти идеальными мишенями для разработки терапевтических вакцин против установленных инфекций и поражений ВПЧ [15,31,32]. Другими белками, полезными для нацеливания на ранние этапы вирусных инфекций, являются E1 (вирусная геликаза) и E2, которые экспрессируются на более ранних этапах, чем E6 и E7, до интеграции вирусного генома [33]. Идеальная терапевтическая вакцина будет нацелена на эти белки с целью индуцировать специфические Т-клетки типа 1 и цитотоксические лимфоциты, способные уничтожать инфицированные и злокачественные клетки [30].…”

Section: лечебные вакциныunclassified

Modern Aspects of Human Papillomavirus Vaccination

Аляутдина¹,

Дармостукова²

2018

Bezopasnost' i risk farmakoterapii

View full text Add to dashboard Cite

Human papillomavirus refers to DNA-containing viruses and infects the skin and mucosal epithelium. One common way is to change the expression of cellular genes by integrating the viral genome into cellular DNA. The reason for the resistance of HPV infection is the presence of complex mechanisms of inhibiting the immune response of the macroorganism. An important infectious agent involved in carcinogenesis are human papillomavirus (HPV) viruses, which cause a significant part of oncological diseases. Viruses create the prerequisites for malignant cells by introducing an oncogene or blockade of suppressor proteins in cells to disrupt the regulation of cell division. Two proteins, E6 and E7, encoded by the DNA of the virus, play a leading role in this process. More than 100 different types of HPV have been identified, and approximately one- third of them infect epithelial cells in the genital tract. HPV is also the cause of carcinoma of the penis, vulva, anus and contribute to the occurrence of more than 40 % of oropharyngeal cancer. To date, the most effective way to combat HPV infection is immunoprophylaxis. To date, there are three commercially available HPV vaccines: Cervarix®, Gardasil®, Gardasil®9. These three vaccines effectively prevent HPV infections, causing the production of neutralizing antibodies that bind to viral particles and block their entry into host cells. However, these vaccines are not effective in eliminating pre-existing infections. Currently, there are no therapeutic vaccines against HPV, approved for use in humans. The review discusses the types of vaccines against HPV infection and the effectiveness of vaccination.

show abstract

Section: лечебные вакциныunclassified

Modern Aspects of Human Papillomavirus Vaccination

Аляутдина¹,

Дармостукова²

2018

Bezopasnost' i risk farmakoterapii

View full text Add to dashboard Cite

show abstract

Plant Production of Vaccine Against HPV: A New Perspectives

Cited by 1 publication

References 99 publications

Modern Aspects of Human Papillomavirus Vaccination

Modern Aspects of Human Papillomavirus Vaccination

Contact Info

Product

Resources

About